Ed Gane

13.3k total citations · 4 hit papers
54 papers, 2.7k citations indexed

About

Ed Gane is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Ed Gane has authored 54 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hepatology, 36 papers in Epidemiology and 11 papers in Surgery. Recurrent topics in Ed Gane's work include Hepatitis C virus research (30 papers), Hepatitis B Virus Studies (27 papers) and Liver Disease Diagnosis and Treatment (25 papers). Ed Gane is often cited by papers focused on Hepatitis C virus research (30 papers), Hepatitis B Virus Studies (27 papers) and Liver Disease Diagnosis and Treatment (25 papers). Ed Gane collaborates with scholars based in New Zealand, United States and Australia. Ed Gane's co-authors include Zobair M. Younossi, Seng Gee Lim, Norah A. Terrault, Anna S. Lok, Marı́a Buti, Grace Lai–Hung Wong, Homie Razavi, Michael P. Manns, Jean–Michel Pawlotsky and Teerha Piratvisuth and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Ed Gane

53 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

2012 834 citations Teerha Piratvisuth, Ed Gane et al. profile →
Hepatitis C virus infection

2017 353 citations Michael P. Manns, Marı́a Buti et al. Nature Reviews Disease Primers profile →
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?

2022 140 citations Grace Lai–Hung Wong, Ed Gane et al. Journal of Hepatology profile →
The scientific basis of combination therapy for chronic hepatitis B functional cure

2023 88 citations Seng Gee Lim, Thomas F. Baumert et al. Nature Reviews Gastroenterology & Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ed Gane New Zealand	22	2.1k	2.1k	348	277	194	54	2.7k
Tai‐Chung Tseng Taiwan	34	3.4k 1.6×	3.5k 1.7×	237 0.7×	232 0.8×	146 0.8×	166	4.1k
Wan Cheng Chow Singapore	19	3.3k 1.6×	3.4k 1.7×	224 0.6×	171 0.6×	206 1.1×	48	3.9k
Tung‐Hung Su Taiwan	34	3.2k 1.5×	3.2k 1.6×	291 0.8×	315 1.1×	225 1.2×	188	4.0k
Anita Kohli United States	24	1.2k 0.6×	1.5k 0.7×	304 0.9×	249 0.9×	216 1.1×	77	2.2k
Chih‐Lin Lin Taiwan	30	2.6k 1.3×	2.8k 1.3×	133 0.4×	269 1.0×	205 1.1×	97	3.2k
Wen‐Juei Jeng Taiwan	26	1.8k 0.9×	1.6k 0.8×	186 0.5×	347 1.3×	322 1.7×	114	2.6k
Chin–Lan Jen Taiwan	25	2.8k 1.4×	3.0k 1.5×	147 0.4×	177 0.6×	150 0.8×	35	3.4k
Ono S Brazil	21	1.2k 0.6×	1.2k 0.6×	309 0.9×	219 0.8×	117 0.6×	101	1.7k
Christoph Welsch Germany	23	1.5k 0.7×	1.2k 0.6×	431 1.2×	385 1.4×	67 0.3×	89	2.1k
Eisuke Murakami Japan	25	1.3k 0.6×	1.1k 0.5×	658 1.9×	459 1.7×	188 1.0×	102	2.1k

Countries citing papers authored by Ed Gane

Since Specialization

Citations

This map shows the geographic impact of Ed Gane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ed Gane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ed Gane more than expected).

Fields of papers citing papers by Ed Gane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ed Gane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ed Gane. The network helps show where Ed Gane may publish in the future.

Co-authorship network of co-authors of Ed Gane

This figure shows the co-authorship network connecting the top 25 collaborators of Ed Gane. A scholar is included among the top collaborators of Ed Gane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ed Gane. Ed Gane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peters, Marion G., Man‐Fung Yuen, Norah A. Terrault, et al.. (2023). Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes. Clinical Infectious Diseases. 78(4). 983–990. 5 indexed citations

Fink, Michael, Paul Gow, Geoffrey W. McCaughan, et al.. (2023). Impact of Share 35 liver transplantation allocation in Australia and New Zealand. Clinical Transplantation. 38(1). e15203–e15203.

Barbieri, Sebastiano, Evan B. Cunningham, Marc van der Valk, et al.. (2023). Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study. Journal of the International AIDS Society. 26(9). e26168–e26168. 3 indexed citations

Lim, Seng Gee, Thomas F. Baumert, Carolina Boni, et al.. (2023). The scientific basis of combination therapy for chronic hepatitis B functional cure. Nature Reviews Gastroenterology & Hepatology. 20(4). 238–253. 88 indexed citations breakdown →

Mak, Lung‐Yi, Ed Gane, Christian Schwabe, et al.. (2022). A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. Journal of Hepatology. 78(4). 684–692. 52 indexed citations

Gane, Ed, Man‐Fung Yuen, Thomas N. Kakuda, et al.. (2022). JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B. Antiviral Therapy. 27(3). 201819616–201819616. 13 indexed citations

Wong, Grace Lai–Hung, Vincent Wai‐Sun Wong, A. Thompson, et al.. (2020). Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. The Lancet. Gastroenterology & hepatology. 5(8). 776–787. 91 indexed citations

Giannelli, Gianluigi, Armando Santoro, Robin Kate Kelley, et al.. (2020). Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS ONE. 15(3). e0222259–e0222259. 46 indexed citations

Younossi, Zobair M., Maria Stepanova, Issah Younossi, et al.. (2019). Patient‐reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Liver International. 39(10). 1837–1844. 22 indexed citations

10.

Dore, Gregory J., Jordan J. Feld, Marianne Martinello, et al.. (2019). Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology. 72(3). 431–440. 26 indexed citations

11.

Faivre, Sandrine, Armando Santoro, Robin Kate Kelley, et al.. (2019). Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver International. 39(8). 1468–1477. 114 indexed citations

12.

Younossi, Zobair M., Maria Stepanova, Harry L.A. Janssen, et al.. (2018). Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. Clinical Gastroenterology and Hepatology. 16(10). 1641–1649.e6. 29 indexed citations

13.

Manns, Michael P., Marı́a Buti, Ed Gane, et al.. (2017). Hepatitis C virus infection. Nature Reviews Disease Primers. 3(1). 17006–17006. 353 indexed citations breakdown →

14.

Bayliss, Julianne, Lilly Yuen, Gillian Rosenberg, et al.. (2016). Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut. 66(11). 2013–2023. 38 indexed citations

15.

Visvanathan, Kumar, Geoff Dusheiko, Michelle Giles, et al.. (2015). Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders. Gut. 65(2). 340–350. 49 indexed citations

16.

Younossi, Zobair M., Maria Stepanova, Fatema Nader, et al.. (2014). Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology. 59(6). 2161–2169. 74 indexed citations

17.

Zeuzem, Stefan, Tarik Asselah, Peter Angus, et al.. (2013). Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results. Antiviral Therapy. 18(8). 1015–1019. 33 indexed citations

18.

Tan, Anthony T., Long Hoàng, Daniel J. Chin, et al.. (2013). Reduction of HBV replication prolongs the early immunological response to IFNα therapy. Journal of Hepatology. 60(1). 54–61. 62 indexed citations

19.

Zeuzem, Stefan, Tarik Asselah, Peter Angus, et al.. (2011). Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection. Gastroenterology. 141(6). 2047–2055. 101 indexed citations

20.

Bartlett, Adam, et al.. (2003). Analysis of Intragraft Gene and Protein Expression of the Costimulatory Molecules, CD80, CD86 and CD154, in Orthotopic Liver Transplant Recipients. American Journal of Transplantation. 3(11). 1363–1368. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact